AI-generated summary
In a mouse model of Alzheimer's disease with beta-amyloid accumulation, the authors report that a 9-day course of transcranial photobiomodulation at 1267 nm was associated with improved neurocognitive scores and higher brain blood oxygen saturation. They attribute the effect to increased clearance of beta-amyloid through meningeal lymphatic vessels. The study was conducted in mice, so the findings do not establish effects in humans.
- Who or what was studied
- Mice with an injected model of Alzheimer's disease and a control group
- Wavelengths
- 1267 nm
- Limits stated in the abstract
- The study was conducted in mice, and the abstract does not report a human sample or the number of animals per group.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 1267 nm
- Energy density (fluence)
- 32 J/cm2
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Photobiomodulation, Control group. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.